Helixmith Co

Helixmith Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Helixmith Co (084990.KQ) as of Oct 21, 2026 is -59.27. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -19.92 — a change of 197.57% (lower).

EV/OCF

-59.27

YoY

197.57%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Helixmith Co is 2025 -59.27 . EV/OCF (Enterprise Value to Operating Cash Flow) of Helixmith Co was 2024 -19.92 . It decreases by 197.57% lower compared to the previous year.

The Helixmith Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-32.75 KRW
Jan 1, 2019
-8.22 KRW
Jan 1, 2020
-8.11 KRW
Jan 1, 2021
-9.89 KRW
Jan 1, 2022
-9.04 KRW
Jan 1, 2023
-14.45 KRW
Jan 1, 2024
-19.92 KRW
Jan 1, 2025
-59.27 KRW
The Helixmith Co EV/OCF history
YEAREV/OCFYoY
-59.27+197.57%
-19.92+37.85%
-14.45+59.85%
-9.04-8.58%
-9.89+21.94%
-8.11-1.41%
-8.22-74.89%
-32.75-73.00%
-121.29+7.65%
-112.67-130.27%
372.21-84.63%
2,421.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Helixmith Co Stock analysis

What does Helixmith Co do? Helixmith Co., Ltd. generates revenue through its Natural Products Business segment, which develops and sells raw materials for functional materials and health functional foods under brands like Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment focuses on developing treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer therapies. Customers include companies in the health and pharmaceutical sectors seeking natural ingredients and specialized medical treatments. The company serves two distinct market segments: one for natural product raw materials and another for advanced biopharmaceutical solutions. The Natural Products Business segment targets clients requiring raw materials for functional materials and health functional foods, leveraging branded products Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment caters to healthcare providers and pharmaceutical firms developing treatments for specific medical conditions, including diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer applications. Both segments operate within the broader health and biotechnology industries, with the company's revenue streams derived from product sales across these specialized markets. Helixmith Co., Ltd. monetizes its research and development efforts through the commercialization of natural substance-based raw materials and biopharmaceutical treatments. The company's product portfolio includes Alex, Murphine, and Nimosin for the natural products market, while its biopharmaceutical segment offers treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer conditions. Revenue is generated from direct sales to businesses in the health, functional food, and pharmaceutical sectors, with no mention of additional revenue streams such as licensing or partnerships. Helixmith Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Helixmith Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Helixmith Co is -59.27 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Helixmith Co changed from -19.92 to -59.27, representing a 197.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Helixmith Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Helixmith Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Helixmith Co

All Key Metrics — Helixmith Co